Inclusion Criteria:

          1. Understand and sign, written Institutional Review Board (IRB)-approved informed
             consent form, and be willing to comply with all study procedures

          2. Participants must be > 18 years of age

          3. Patient is able to take oral medications

          4. Histologically or cytologically documented disease

          5. Unresectable, locally advanced or metastatic solid tumor for which no standard therapy
             is recognized or for which standard therapy has failed

          6. Has evaluable or measurable disease by RECIST v1.1 criteria

          7. Provide tumor tissue and/or archival tissue from original diagnostic block, if
             available for biomarker analysis

          8. Performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) scale

          9. Normal auditory acuity: defined as a normal age-related audiogram without significant
             hearing loss.

         10. Must have adequate bone marrow and renal/hepatic function at the screening and
             baseline visits, defined as:

               1. Absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L without granulocyte
                  colony-stimulating factor (G-CSF) support within 7 days preceding the lab
                  assessment.

               2. Platelet ≥100 x 10^9/L, without transfusion within 7 days preceding the lab
                  assessment

               3. Hemoglobin ≥9 g/dL, without transfusion support within 7 days preceding the lab
                  assessment.

               4. Activated partial thromboplastin time/ partial thromboplastin time (aPTT/PTT)
                  ≤1.5 x ULN

               5. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT)≤ 2.5 × upper
                  limit of normal (ULN) (if liver metastases are present, then≤5 x ULN is allowed)

               6. Total serum bilirubin≤1.5 x ULN, (except for patients with known Gilbert's
                  Syndrome≤3 x ULN is permitted)

               7. Thyroid function (T4, and T3) are within normal limits

               8. Renal: Serum creatinine < 1.5 x ULN or creatinine clearance ≥60 mL/min/1.73m2 for
                  patients with serum creatinine levels above 1.5 x ULN.

               9. Any Grade 3 or higher lab abnormalities should be discussed and approved by the
                  Medical Monitor prior to enrollment (even if not considered clinically
                  significant);

         11. Patient compliance and geographic proximity (as determined by the Principal
             Investigator) that allow adequate follow-up.

         12. Both male and female patients must be willing to consent to using highly effective
             contraception prior to study entry, while on treatment and at least 3 months
             thereafter.

        Exclusion Criteria:

          1. Have a seizure disorder where > 1 seizure has occurred within the last year.

          2. Patient has clinically significant cardiovascular disease (e.g., significant cardiac
             conduction abnormalities, uncontrolled hypertension, myocardial infarction, cardiac
             arrhythmia or unstable angina, New York Heart Association Grade 3 or greater
             congestive heart failure, serious cardiac arrhythmia requiring medication, Grade 2 or
             greater peripheral vascular disease, and history of cerebrovascular accident (CVA))
             within 6 months of enrollment.

          3. History or presence of an abnormal electrocardiogram (ECG) that, in the Investigator's
             opinion, is clinically meaningful. Screening QTcF interval >480 ms is excluded. In the
             event that a single QTcF is >480 ms, the subject may enroll if the average QTcF for
             the 3 ECGs is < 480ms. For patients with an intraventricular conduction delay (QRS
             interval >120ms), the JTc interval may be used in place of the QTcF with Sponsor
             approval. The JTc must be <340 ms if JTc is used in place of the QTcF. Patients with
             an intraventricular delay due to a left bundle branch block are excluded; Note: QTcF
             prolongation due to pacemaker may enroll if the JTc is normal.

          4. Patient with treated (surgically excised or irradiated) and stable brain metastases
             are eligible as long as the treatment was at least 4 weeks prior to initiation of
             study drug and baseline brain computed tomography (CT) with contrast or magnetic
             resonance imaging (MRI) within 2 weeks of initiation of study drug is negative for new
             brain metastases. Subjects with stable brain metastases must not require therapy with
             corticosteroids

          5. Have major surgery, other than diagnostic surgery, within 4-weeks prior to Day 1

          6. Have active, bacterial, viral, or fungal infections, requiring systemic therapy

          7. Women who are pregnant or lactating. NOTE: Women of childbearing potential (WOCBP)
             must have a "negative" serum pregnancy test within one week prior to treatment.

             a) Women not OCBP defined as any of the following: i) Postmenopausal with > 1 year
             since last menses and:

        (1) If younger than 65 years old, with a follicle-stimulating hormone (FSH) > 40 mIU/mL (2)
        If older than 65 years old and not on hormone replacement therapy (HRT), with a FSH > 30
        mIU/mL (3) If older than 65 years old and on HRT, the FSH requirement in not applicable.
        Postmenopausal females on HRT will be allowed if the treatment is stable for at least 6
        months prior to dosing of study drug(s) (4) Written medical documentation of being
        sterilized (e.g. hysterectomy, double oophorectomy, bilateral salpingectomy) with the
        procedure performed at least 6 months prior to dosing study drug(s). Note: Tubal ligation
        is not considered a form of permanent sterilization (5) Should a woman become pregnant or
        suspect she is pregnant while participating in this study, she should inform her treating
        physician immediately.

        8) Have undergone treatment with radiation therapy, surgery, chemotherapy, immunotherapy or
        investigational therapy within one month prior to study entry (6 weeks for nitrosoureas or
        Mitomycin C). Patients may also not have any unresolved toxicity > grade 1 from previous
        anticancer therapy, except for stable chronic toxicities that are not expected to resolve
        (i.e. peripheral neuropathy, alopecia etc.)

        9) Have an unwillingness or inability to comply with procedures required in this protocol

        10) Has jaundice or known current active liver disease from any cause, including hepatitis
        A (hepatitis A virus immunoglobulin M (IgM) positive), hepatitis B (hepatitis B virus
        surface antigen (HBsAg) positive), or hepatitis C (hepatitis C virus (HCV) antibody
        positive, confirmed by HCV ribonucleic acid)

        11) Have a serious nonmalignant disease that in the opinion of the Investigator and/ or the
        Medical Monitor, could compromise protocol objectives in the opinion of the investigator
        and/or the sponsor

        12) Patients who are currently receiving any other investigational agent or who have
        received an investigational agent within the last 28 days

        13) Known gastrointestinal disease or procedure that could interfere with the absorption of
        study drug, including inability to swallow whole capsules or conditions that may interfere
        with absorption The medical monitor should be contacted for any questions regarding this
        exclusion criterion

        14) Patients who have exhibited allergic reactions to a similar structural compound,
        biological agent, or formulation